All Releases |
|---|
 |
XOMA Regains NASDAQ Compliance
Sep 2, 2010
|
10.3 KB
|
| |
BERKELEY, Calif., Sep 2, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMAD), a leader in the discovery and development of therapeutic antibodies, today announced that NASDAQ has notified the Company that it regained compliance with the minimum $1.00 per share bid price requirement for continued listing. Accordingly, the Compan...
|
|
|
XOMA Appoints Jack L. Wyszomierski to Its Board of Directors
Aug 26, 2010
|
10.7 KB
|
| |
BERKELEY, Calif., Aug 26, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMAD), a leader in the discovery and development of antibody therapeutics, announced that Jack L. Wyszomierski, a seasoned executive with extensive leadership experience in the pharmaceutical and life sciences industries, has been elected to XOMA's Board of...
|
|
|
XOMA Receives $4 Million for Sale of Royalty Interest in CIMZIA(R)
Aug 18, 2010
|
10.0 KB
|
| |
BERKELEY, Calif., Aug 18, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that it has sold its royalty interest in CIMZIA(R) (certolizumab pegol) marketed by UCB S.A. for $4 million to an undisclosed buyer. The manufacture of CIMZIA is cove...
|
|
|
XOMA Announces Reverse Stock Split
Aug 17, 2010
|
11.3 KB
|
| |
BERKELEY, Calif., Aug 17, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that its board of directors has approved a 1-for-15 share consolidation, or reverse stock split, that will become effective with the opening of trading on August 18, ...
|
|
|
XOMA Reports Second Quarter 2010 Financial Results
Aug 9, 2010
|
20.8 KB
|
| |
BERKELEY, Calif., Aug 9, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the second quarter ended June 30, 2010 and provided a general business update.
"With the completion of enrollment in the Phase 2b clinica...
|
|
|
XOMA 052 Designated Orphan Drug by FDA for Treatment of Behcet's Disease
Aug 4, 2010
|
12.9 KB
|
| |
BERKELEY, Calif., Aug 4, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously an...
|
|
|
XOMA to Announce 2010 Second Quarter Financial Results and Host Webcast Conference Call on August 9, 2010
Aug 2, 2010
|
10.4 KB
|
| |
BERKELEY, Calif., Aug 2, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that the company will host a webcast conference call on Monday, August 9, 2010 at 4:30 pm Eastern time to discuss its 2010 second quarter financial results and provide a gene...
|
|
|
XOMA 052 Orphan Drug Designation for Behcet's Disease Recommended by European Medicines Agency
Jul 29, 2010
|
12.9 KB
|
| |
BERKELEY, Calif., Jul 29, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medicines Agency (EMA) has adopted a positive opinion and recommends the granting of orphan medicinal product...
|
|
|
XOMA Receives $750,000 Milestone Payment From AVEO Pharmaceuticals
Jul 26, 2010
|
10.2 KB
|
| |
BERKELEY, Calif., Jul 26, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO). The milestone payment resulted from AVEO's recent initiation ...
|
|
|
XOMA Enters Into $30 Million Committed Equity Financing Facility
Jul 23, 2010
|
10.4 KB
|
| |
BERKELEY, Calif., Jul 23, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA) today announced that it has entered into a committed equity financing facility under which it has the option to sell up to $30 million of its registered common shares to Azimuth Opportunity Ltd. over a 12-month period. XOMA is not obligated to utilize ...
|
|
|
XOMA Achieves Planned Enrollment Goal for Phase 2b Clinical Trial of XOMA 052 in Type 2 Diabetes
Jun 30, 2010
|
11.3 KB
|
| |
BERKELEY, Calif., Jun 30, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in the nex...
|
|
|
Preclinical Results With XOMA 052 in Type 2 Diabetes Presented at American Diabetes Association 70th Scientific Sessions
Jun 26, 2010
|
13.4 KB
|
| |
ORLANDO, Fla., Jun 26, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in com...
|
|
|
Journal Article in Endocrinology Highlights Preclinical XOMA 052 Data in Type 2 Diabetes
Jun 22, 2010
|
13.6 KB
|
| |
BERKELEY, Calif., Jun 22, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the publication of data from a mouse model of diet-induced obesity in the June, 2010 edition of the journal Endocrinology. The data showed that mice treated with XOMA 052 b...
|
|
|
Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease
Jun 17, 2010
|
14.8 KB
|
| |
ROME, Jun 17, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses ...
|
|
|
NASDAQ Grants XOMA's Request for Continued Listing
Jun 15, 2010
|
10.3 KB
|
| |
BERKELEY, Calif., Jun 15, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that a NASDAQ Listing Qualifications Panel (the "Panel") has granted the company's request for an extension of time, as permitted under NASDAQ's Listing Rules, to com...
|
|
|
XOMA to Host Conference Call to Present Initial Results From XOMA 052 Clinical Trial in Behcet's Disease
Jun 10, 2010
|
10.6 KB
|
| |
BERKELEY, Calif., Jun 10, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the company will host a webcast conference call on Thursday, June 17, 2010 at 11:00 a.m. Eastern time to present preliminary results from a clinical trial evaluating X...
|
|
|
Abstract Published on Initial Results From XOMA 052 Clinical Trial in Behcet's Disease
May 12, 2010
|
13.5 KB
|
| |
BERKELEY, Calif., May 12, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the publication of an abstract titled, "Safe, Rapid-onset and Sustained Biological Activity of IL-1 beta Regulating Antibody XOMA 052 in Resistant Uveitis of Behcet's Disea...
|
|
|
XOMA Reports First Quarter 2010 Financial Results
May 6, 2010
|
19.9 KB
|
| |
BERKELEY, Calif., May 6, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the first quarter of 2010 and provided a general business update.
"The first months of 2010 were highlighted by progress on multiple fron...
|
|
|
XOMA 052 Mechanism of Action Results Published in Journal of Biological Chemistry
Apr 30, 2010
|
11.3 KB
|
| |
BERKELEY, Calif., Apr 30, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the publication of a peer-reviewed paper describing the novel mechanism of action of XOMA 052, a potent, high affinity antibody that inhibits the inflammatory cytokine inte...
|
|
|
XOMA to Announce 2010 First Quarter Financial Results and Host Webcast Conference Call on May 6
Apr 29, 2010
|
10.0 KB
|
| |
BERKELEY, Calif., Apr 29, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that the company will host a webcast conference call on Thursday, May 6, 2010 at 4:30 pm Eastern time to discuss 2010 first quarter financial results and provide a general b...
|
|
|
$0.01
